Highest-materiality recent filing
bioAffinity CyPath Lung unit sales nearly 300% higher in April 2026 vs 2025
Record monthly CyPath Lung unit sales in April 2026; preliminary data shows ~300% YoY increase over April 2025.
bioAffinity Q1 2026: CyPath Lung sales +146% YoY, revenue $1.4M, net loss $3.6M
CyPath Lung unit sales rose 146% YoY; testing revenue up 114% to $361,000.
BioAffinity stockholders approve reverse stock split, 2024 plan share increase to 1M
Stockholders approved reverse stock split at ratio of 1-for-2 to 1-for-250, at board's discretion.
bioAffinity Q1 2026 CyPath Lung unit sales surge 146% YoY, beat projections
Q1 2026 CyPath Lung unit sales up 146% YoY, exceeding internal projections on accelerating physician adoption.
bioAffinity 2025 revenue $6.2M; CyPath Lung revenue up 87% YoY, net loss $14.9M
Total revenue $6.2M, down 34% from $9.4M in 2024 due to discontinuing unprofitable pathology services.
bioAffinity initiates 2K-patient longitudinal study for CyPath Lung diagnostic
2,000-patient longitudinal study to evaluate CyPath Lung for early lung cancer detection in high-risk patients with nodules 6-29mm.
bioAffinity Technologies maintains CAP accreditation for lab subsidiary PPLS
Precision Pathology Laboratory Services (PPLS) passed rigorous CAP on-site inspection, retaining gold-standard accreditation.
bioAffinity Q3 2025: revenue down to $1.5M, CyPath Lung revenue up 122% YoY, net loss $5.1M
Total revenue $1.5M in Q3 2025, down 38% from $2.4M in Q3 2024 due to discontinuation of unprofitable pathology services.
bioAffinity reports CyPath Lung test volume up 111% in Oct vs 2025 monthly avg
October test volume increased 111% over 2025 monthly average; Q3 volume rose 95% sequentially.
bioAffinity regains Nasdaq compliance; stock continues trading on Capital Market
Received Nasdaq letter Oct 14 confirming compliance with minimum bid price ($1.00) and stockholders' equity ($2.5M) rules.
bioAffinity closes $4.8M public offering; Nasdaq compliance extension received
Gross proceeds of $4.8M from sale of 1,921,761 shares/pre-funded warrants at $2.50/$2.493 per unit.
bioAffinity Technologies announces 1-for-30 reverse stock split effective Sept 19, 2025
1-for-30 reverse stock split effective at open of trading on Nasdaq on September 19, 2025.
Increased floor price in May 2025 and August 2025 warrants from $0.10 to $0.15, effective August 12, 2025.
bioAffinity closes $1.45M capital raise and reclassifies warrants adding $2.8M to equity
Private placement of 990 Series B Preferred shares convertible into ~4.3M common at $0.23/sh and warrants for ~6.7M shares at $0.352/sh, gross proceeds ~$1.2M.
Nasdaq notified Company on Aug 7 that it failed to regain minimum bid price by Aug 6 and is ineligible for second 180-day period.
All seven proposals passed at July 25, 2025 Annual Meeting.
bioAffinity Technologies: CyPath® Lung detects Stage 1A tumor missed by PET scan, bronchoscopies
CyPath® Lung identified a Stage 1A neuroendocrine tumor after PET scan, bronchoscopies and serum tumor marker suggested non-cancerous inflammation.
bioAffinity receives China patent allowance for lung cancer diagnostic using flow cytometry
CNIPA allowed patent 'System and Method for Determining Lung Health' covering use of antibodies and TCPP porphyrin to label sputum cells for lung cancer detection via flow cytometry.
bioAffinity receives Nasdaq delisting notice; equity of $1.44M below $2.5M minimum
Stockholders' equity was $1,439,404 as of March 31, 2025, well below the $2,500,000 minimum.
On April 12, 2025, Stuart Diamond, a member of the board of directors (the “Board”) of bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), notified the Company of his decision not to stand for re-election at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).
On October 4, 2024, the Board of Directors (the “Board”) of bioAffinity technologies, Inc. (the “Company”) appointed J. Michael Edwards, who has served as the Company’s Interim Chief Financial Officer, as a consultant, since September 2024, to serve as Chief Financial Officer of the Company, effective November 5, 2024.
Michael Dougherty notified bioAffinity Technologies, Inc. (the "Company") of his decision to resign from his position as the Company’s Chief Financial Officer and Principal Accounting Officer to pursue other opportunities.
the Board of Directors of the Company appointed, effective as of September 16, 2024, Michael Edwards, age 57, to serve as the Company’s Interim Chief Financial Officer and Principal Accounting Officer.
Max materiality 0.85 · Median 0.50 · Most common event other_material